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SUMMARY
Objective: Analyze the use of appetite suppressants in Brazil in 2009, according to the 
characteristics of users, healthcare system, and other drugs. Methods: Pharmaconecono-
metric study of cross-sectional data  to analyze the relationship between the use of ap-
petite suppressants (mg/per capita) and the independent variables selected (gender, 
race/color, age, schooling, income, health insurance coverage, and use of fluoxetine and 
chlordiazepoxide) using multiple linear regression analysis. This study used these vari-
ables in level of aggregation by states for 2009. The analyses were performed using the 
Gretl software. Results: We highlight that São Paulo showed the highest use of appe-
tite suppressants with 97.3 mg/per capita, followed by Goiás with 94.8 mg/per capita. 
The lowest use of appetite suppressants was seen in Ceará (3.8 mg/per capita). The biggest 
fluoxetine users were in Rio Grande do Sul, with 58.0 mg/per capita, and in Goiás, with 
51.5 mg/per capita. Ceará showed the lowest fluoxetine use (2.3 mg/per capita). For 
chlordiazepoxide, the highest values were seen in Minas Gerais (7.5 mg/per capita) and 
in Rio de Janeiro (4.8 mg/per capita), while Amazonas (0.08 mg/per capita) showed the 
lowest use. Based on regression analysis, we can highlight: 1) the use of appetite suppres-
sants is related to income, education, and fluoxetine use; and 2) race/color, gender, age, 
health insurance coverage, and use of chlordiazepoxide showed no relation to the use of 
appetite suppressants. Conclusion: These evidences may contribute to the improvement 
of regulatory actions, sanitary surveillance, and ethical conduct, particularly with regard 
to the concomitant use of appetite suppressants and fluoxetine, which is prohibited by 
the Federal Council of Medicine (Conselho Federal de Medicina) and also by National 
Health Surveillance Agency (Anvisa –Agência Nacional de Vigilância Sanitária).
Keywords: Regression analysis; appetite suppressants; pharmaceutical economics; 
obesity.
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INTRODUCTION
Little is known about the correlation between the use of 
appetite suppressant drugs and other sociodemographic 
and health care variables.1 This is a serious issue because 
obesity is considered a public health problem due to the 
increased prevalence worldwide. This health condition, 
which is included in the group of non-transmitted chronic 
diseases, can be dened as the excessive accumulation 
of body fat in such a way that it brings health damage to 
people2. 
Since 1980, the prevalence of obesity has increased 
three times or more around the world, probably due to 
changes in dietary habits and life style3. An analysis of 
epidemiological studies performed by Farrigan e Pang4 
indicates that the prevalence of obesity in countries with 
the largest pharmaceutical market (United States, France, 
Germany, Italy, Spain, United Kingdom, and Japan) was es-
timated, on average, as 3.8% annually along 10 years (2000 
through 2010), while in countries like Brazil this growth 
in the same period was 5.5%. Then an estimate was made 
showing that the number of obese adults in the seven main 
pharmaceutical markets (United States, France, Germany, 
Italy, Spain, United Kingdom, and Japan) grew from 95 
million in 2000 to 139 million in 2010. Furthermore, less 
than 25% of potential patients are formally diagnosed as 
obese; among these, less than 20% are treated with phar-
macological therapy.
Another projection made by the World Health Organi-
zation (WHO) points out that in 2015, approximately 2.3 
billion adults will be overweight and more than 700 million 
will be obese.  The United States are currently the largest 
market selling anti-obesity drugs, having around 68% of 
its population overweight or obese, followed by the United 
Kingdom and other European countries. However, China, 
Russia, India, and Brazil may soon start to match the west-
ern countries in terms of their obese populations. For ex-
ample, obesity in China and levels of excessive weight are 
foreseen to reach 665 to 670 million individuals by 20155.
Data published by the Ministry of Health show an 
increasing frequency of people who are overweight and 
obese in Brazil. In 2006, the percentage of individuals who 
were overweight was 42.7% and in 2010 this amount went 
up to 48.1%. Regarding obese people, this variation ranged 
from 11.4% (2006) to 15.0% (2010)6. 
The conventional method of reducing body weight in-
cludes the practice of physical activity, diet, and modi-
cation in the individual’s behavior. Bariatric surgery has 
proven eective for weight loss on the long run, but it is 
usually applied to morbidly obese patients who have re-
peatedly failed in other treatment modalities. The use of 
appetite suppressants has been a quite recurrent alterna-
tive in the medical scenery1. The e cacy of these drugs 
is described as modest1 and their clinical safety has been 
questioned because in many countries such products are 
no longer sold, and in others they still have not even been 
registered for sale1,7. 
The appetite suppressant drugs sold in Brazil are am-
phepramome, fenproporex and mazindol, which have 
been sold in the Brazilian market for more than 30 years; 
orlistat, which was registered by the National Health Sur-
veillance Agency (Anvisa) in February, 1998; and sibutra-
mine, which was granted its registration in the country 
in March, 19987. These drugs, except for orlistat, are part 
of the Administrative rule SVS/MS N. 344, from May 12, 
1998, which promotes a rigorous sanitary control on pre-
scription, dispensation, and use of such products in the 
country8. This norm classies them as anorexigenic psy-
chotropic drugs pertaining to the B2 list, whose medical 
prescription forms in blue are demanded for drug dispen-
sation in pharmacies and/or drugstores duly accredited by 
the National System for the Management of Controlled 
Products (Sistema Nacional de Gerenciamento de Produ-
tos Controlados – SNGPC) from Anvisa8,9. 
Recently, Anvisa has promoted a public hearing (Feb-
ruary, 2011) in order to hear society about its intention  to 
cancel the registration of drugs with sibutramine, amphe-
pramone, mazindol, and fenproporex in the country. In 
June, 2011, as a way to subsidize with further evidence the 
decision making of Anvisa’s  managers, an international 
panel of specialists7 was held. Up to the end of this work, 
the agency had not issued any decision on the permanence 
or cancellation of these drugs (or some of them) in the 
Brazilian pharmaceutical market.
The objective of this work was to analyze the use of 
appetite suppressants which are under the Administra-
tive rule SVS/MS N. 344/1998 in Brazil in 2009, accord-
ing to the characteristics of users (gender, age, education, 
income, and race/color), healthcare system (health insur-
ance coverage rate), and use of fluoxetine (antidepressive) 
and chlordiazepoxide (ansiolytic).   Literature data indicate 
that fluoxetine and chlordiazepoxide were the drugs most 
associated with concomitant use of appetite suppressants10.
METHODS AND HYPOTHESES 
Pharmacoeconometric study11 of cross-sectional data to 
analyze the relationships between the use of appetite sup-
pressants and variables, such as gender, race/color, age, 
income, health insurance coverage, and use of fluoxetine 
and chlordiazepoxide, using an econometric model for a 
multiple linear regression analysis. The study used these 
variables in a level of aggregation per units of the federa-
tion (UF) referring to 2009; data collection was performed 
between March and April, 2011.
The econometric model established was:
(1) CMAi = 0 + 1FEMi + 2RACi + 3IDAi + 4ESCi + 
5RENi + 6TCPi + 7CFLi + 8CCLi + ui
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t CMAi – Use of appetite suppressant drugs in mil-
ligrams (mg)/per capita, represented by the active 
ingredients amphepramone, fenproporex, mazindol, 
and sibutramine sold in the Brazilian pharmaceuti-
cal market in industrialized and magistral formula-
tions per unit of the federation. The population with 
an indication for taking these drugs (aged 18 to 64 
years) was used to calculate the per capita use of ap-
petite suppressant drugs.
t FEMi – proportion of women per unit of the fede-
ration (UF).
t RACi – proportion of white individuals per UF.
t IDAi – proportion of individuals aged 60 years or 
older per UF.
t ESCi – ratio of individuals aged 25 years or older 
with 15 or more years of schooling.
t RENi –average monthly family income per capita in 
Brazilian Real of the 10% richest people per UF.
t TCPi – health insurance coverage rate in percentage 
per UF.
t CFLi – use of fluoxetine, in mg/per capita, sold in 
industrialized and magistral formulations per UF.
t CCLi – use of chlordiazepoxide, in mg/per capita, 
sold in industrialized and magistral formulations 
per UF.
t ui – represents the stochastic error of the model 
estimate.
To calculate the use in mg/per capita of fluoxetine and 
chlordiazepoxide we used the same age group of the pop-
ulation of the appetite suppressant drugs.
The database was formed from difterent sources of 
evidence available. Such sources were the determining 
factor in choosing the year 2009, as for the preceding and 
subsequent years it was not possible to gather the values 
for all the variables studied. Thus, the values of the FEM, 
RAC, IDA, ESC, and REN variables were obtained from 
the National Research of Samples by Domiciles (Pesquisa 
Nacional de Amostras por Domicílios – PNAD) from 
2009, published by IBGE (Brazilian Institute for Geog-
raphy and Statistics). The data from TCP were collected 
in the Supplementary Health National Agency (Agência 
Nacional de Saúde Suplementar – ANS) website, while 
the CMA, CFL, and CCL values were extracted from 
the SNGPC database, from Anvisa. SNGPC is a sanitary 
surveillance information system which captures data on 
purchase and sale of drugs under Administrative rule 
SVS/MS N. 344/1998, using XML ftles. Up to 2009, there 
were 35,031 pharmacies/drugstores accredited at SNGPC 
spread among 3,494 Brazilian municipalities, which sent 
3,175.863 XML ftles to Anvisa’s system base.
Descriptive statistical analysis was used to calculate 
measures of central tendency and dispersion. The degree 
of linear association between the independent variables 
was evaluated by calculating the correlation coeft cient. A 
model of multiple linear regression was estimated with all 
the variables studied and validated in terms of heterosce-
dasticity (White’s test) and colinearilty (variance inflation 
test, VIF). All analyses were performed with the Gretl 
software. 
Because this research is based on database records 
(secondary data) publicly available or obtained through 
institutional contact and maintains the anonymity of the 
interviewees, submission to the Research Ethics Commit-
tee was not necessary. 
The hypotheses to be tested in the econometric model 
are described bellow with their respective arguments.
H1: CMA IS HIGHER AMONG WOMEN 
Data reported by Cawley and Rizzo1 suggest that soci-
ology and psychology studies consider obesity more as-
sociated with low self-esteem in women than in men, as 
well as the existence of a greater social stigma for women. 
Khan et al.12, in a study to estimate the prevalence of use 
of prescription drugs for weight loss, found that the use 
of these products was more common among women than 
men. In Brazil, a study performed by Carneiro, Guerra-
Júnior, and Acúrcio10 in Belo Horizonte evidenced the ab-
solute predominance of the use of these drugs by women 
in relation to men in a ratio of 10:1. 
H2: CMA IS HIGHER AMONG WHITE PEOPLE
According to Cawley and Rizzo1, there are distinct dif-
ferences regarding the use of weight loss drugs between 
races/color. In this study, we assume that white race/color 
individuals are more prone to use appetite suppressant 
drugs in the country.
H3: CMA DECREASES WITH AGE 
According to Cawley and Rizzo1, the main reason for the 
CMA is becoming physically attractive. For people out-
side the fertile age, the social cost of not being attrac-
tive may decrease. Although the consequences of obesity 
worsen with age, the authors suspect that such situation 
contributes to these people having a bigger concern for 
the use of drugs destined to treat comorbidities (type II 
diabetes, dyslipidemia, hypertension), instead of obesity.
H4: CMA INCREASES WITH EDUCATION
According to Grossman and Kaestner, quoted by Caw-
ley and Rizzo1, education is strongly correlated to good 
health, as it leads people to choose a better-input mix and 
use it in a more eft cient way for producing health. Thus, 
people with higher education degree are more prone to 
the CMA. A study of Spanish data indicates that the prob-
ability of an individual using medication is higher as his 
level of education increases13.
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H5: CMA INCREASES WITH INCOME 
As proposed by Cawley and Rizzo1, we also assume that 
appetite suppressant drugs are considered a normal asset. 
So, by keeping other variables constant, we see that with an 
increased income people tend to buy more of these drugs.
H6: CMA IS HIGHER AMONG INDIVIDUALS WITH HEALTH IN-
SURANCE 
Administrative rule SVS/MS N. 344/98 determines that the 
drugs which are the object of this study can only be sold 
with their prescription retention in the pharmaceutical 
establishment and with the bookkeeping in the SNGPC8,9. 
Thus, the rst stage for the use of appetite suppressants 
drugs is that the patient be seen by a doctor. In this sense, 
people who have health insurance in Brazil have a better 
access to this professional and, consequently, it might be 
easier for them to acquire such products.
H7: CMA IS POSITIVELY CORRELATED TO THE USE OF FLUOXETINE 
OR CHLORDIAZEPOXIDE
According to Carneiro, Guerra-Júnior and Acúrcio10, 
among patients who received anorexigenics, 91.8% had a 
prescription for the concomitant use of another substance, 
with fluoxetine and chlordiazepoxide as most associated 
drugs.
RESULTS 
The descriptive analyses of the variables studied are shown 
in Table 1. We can notice that for some variables, such as 
CMA, RAC, TCP, and CFL, there is a greater variability 
among their minimum and maximum values.
The state of São Paulo had the highest CMA, 97.3 mg/per 
capita, followed by Goiás, with 94.8 mg/per capita. The 
lowest use was veriúed in Ceará (3.8 mg/per capita). 
The highest proportion of women was seen in the Federal 
District, Pernambuco, and in Rio de Janeiro, all with 53%, 
while Amapá (49.0%) and Tocantins (49.0%) presented 
the lowest proportions.
The southern region states presented the highest pro-
portions of individuals who claimed to be of the race/
white color in the following decreasing order: Santa Ca-
tarina (85.7%), Rio Grande do Sul (81.3%), and Paraná 
(71.8%). The lowest proportions of white individuals 
were registered in Amazonas (21.2%) and Bahia (21.8%). 
In relation to the proportion of individuals aged 60 years 
or older, the states of Rio de Janeiro (15.0%) and Rio 
Grande do Sul (13.7%) were the úrst and second, respec-
tively, while Roraima (4.8%) was the state with the lowest 
proportion of individuals in this age group. 
The highest proportion of individuals aged 25 years 
or older with 15 or more years of education was found at 
the Federal District (23.0%) and Rio de Janeiro (13.8%), 
while the state of Maranhão showed the lowest propor-
tion (4.2%). The average monthly family income per 
capita of the richest 10% were found in the Federal Dis-
trict (R$ 7,987.92) and in Rio de Janeiro (R$ 4,496.49). 
The state of Alagoas presented the lower income 
(R$ 1,846.56).
The state of São Paulo (40.4%) and Rio de Janeiro 
(33.8%) presented the highest rates of health insurance 
coverage, while Maranhão (4.7%) had the lowest rate. 
The states with the highest consumption of fluoxetine 
were Rio Grande do Sul with 58.0 mg/per capita and 
Goiás with 51.5 mg/per capita. Ceará (2.3 mg/per capi-
ta) registered the lowest consumption of this drug. For 
chlordiazepoxide, the highest consumption was found 
in Minas Gerais (7.5 mg/per capita) and Rio de Janeiro 
(4.8 mg/per capita), while Amazonas (0.08 mg/per capi-
ta) showed the lowest consumption.
The correlation coeú cients between the independent 
variables are presented in Table 2. There is a high and 
positive correlation between the CFL and RAC varia- 
bles (0.8116) and also between the REN and ESC 
variables (0.9590), that is, these variables move in the 
same direction and with a high linear association degree. 
The remaining variables do not present values > 0.80, 
Table 1 – Values of the measurements of central tendency and dispersion of studied variables, Brazil, 2011 (no of observations = 27)
Variables Mean ± SD Median (min-max)
CMA (mg/per capita) 39.4 ± 31.9 28.1 (3.8-97.3)
FEM (%) 51.0 ± 0.9 51.0 (49.1-53.0)
RAC (%) 39.2 ± 18.2 36.3 (21.2-85.7)
IDA (%) 9.8 ± 2.4 10.3 (4.8-15.0)
ESC (%) 9.2 ± 0.6 8.7 (4.2-23.0)
REN (R$) 2,981.70 ± 1,211.50 2,662.70 (1,845.60-7,987.90)
TCP (%) 14.6 ± 9.0 10.8 (4.7-40.4)
CFL (mg/per capita) 22.0 ± 18.1 15.4 (2.3-58.0)
CCL (mg/per capita) 1.8 ± 1.8 1.2 (0.08-7.5)
SD, standard deviation.
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which means there is no linear association. It is note-
worthy that that no correlation was found to be negative 
among the studied variables.
The econometric model was estimated by minimal 
ordinary squares, considering the variables previouslty 
described for the 27 units of the federation in Brazil. The 
model results are shown in Table 3.
The results of the estimated econometric model showed 
that when all independent variables are equal to zero, the 
CM will be 111.65 mg/per capita. The angular coe cients 
estimated for ESC, REN, and CFL were statistically signi-
cant, according to statistical values of p-value in Table 3. 
However, angular coe cients ESC and CFL showed to be 
coherent with the hypotheses raised by the study. By the 
value of the ESC angular coe cient, one can say that an 
increase of 1% in ESC produces an increase of 6.46 mg/per 
capita in CMA. Similarly, an increase of 1 mg/per capita in 
CFL produces an increase of 1.66 mg/per capita in CMA.
The angular coe cient of the IDA and TCP variables 
were estimated with a correct signal; that is, they com-
ply with the study hypothesis, but were not signicantly 
dierent from zero. It is also worth highlighting that ap-
proximately 85% of the variations in CMA by unit of the 
federation can be explained by the eight previous variables 
together, incorporated into the econometric model, as 
well as the constant and the angular coe cients together 
are statistically dierent from zero with 5% signicance 
(p-value(F) < 0.0001).
According to the VIF, there is a problem of colinearity 
between the ESC (18.06) and REN (16.05) variables. For 
the remaining variables, the VIF values ranged from 1.90 
for FEM to 5.37 for CFL, which means there are no perfect 
linear relations. Through White’s test (p=0.126486), the 
model’s variance is constant, that is, there is no heterosce-
dasticity.
DISCUSSION 
According to our literature review, this is the rst pharma-
coeconometric study performed in Brazil that explores the 
correlation between the use of appetite suppressant drugs 
and sociodemographic and heath care variables, analyzed 
from an econometric model. There is a scarcity of national 
studies using the econometric method to assess the cor-
relation between the use of drugs and important variables 
that may influence, decreasing or increasing such need of 
the country’s population.
Independent variables adopted in the econometric 
model sought to explicitly incorporate, for the studied 
FEM RAC ESC IDA TCP REN CFL CCL Variables
1.0000 0.2567 0.3216 0.4935 0.4348 0.4023 0.2101 0.2681 FEM
  1.0000 0.4919 0.6022 0.7112 0.4242 0.8116 0.3695 RAC
    1.0000 0.1136 0.6136 0.9590 0.6601 0.3461 ESC
      1.0000 0.5719 0.1335 0.4594 0.5059 IDA
        1.0000 0.5640 0.6947 0.6215 TCP
          1.0000 0.6122 0.3302 REN
            1.0000 0.5536 CFL
              1.0000 CCL
Table 2 – Linear association between the independent variables studied, Brazil, 2011 (no of observations = 27)
Dependent variable: CMA Coefcient Standard error p-value
Constant 111.65 180.84 0.5447
FEM -173.27 373.18 0.6480
RAC -30.77 31.11 0.3359
ESC 6.46 2.81 0.0338*
IDA -1.97 1.81 0.2899
TCP 0.80 0.53 0.1484
REN -0.02 0.008 0.0263*
CFL 1.66 0.31 < 0.0001*
CCL -0.94 2.05 0.6517
No of observations 27    
Adjusted R2 0.84727    
*Statistically signiﬁcant with 95% conﬁdence.
Table 3 – Results of regression equation 1, Brazil, 2011
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aggregated level, elements that the analysis assumes as 
determinants for the use of appetite suppressant drugs in 
2009 in the units of the federation. In this sense, in the 
estimated econometric model, the variable with the high-
est power of explaining the variation in the use of appetite 
suppressant drugs is the use of fluoxetine.
The study shows that 91.8% of patients who received 
anorexigenics were also concomitantly prescribed some 
other substance, with fluoxetine and chlordiazepoxide as 
the most associated drugs10. Carlini et al.14 indicate that 
fluoxetine is used as suggestive for weight loss, and not for 
treating depression. These ndings suggest that the con-
comitant use of appetite suppressant drugs and fluoxetine 
is being used as means to obtain more eectiveness in the 
treatment of obesity or weight loss in a shorter period of 
time.   However, in a metanalysis study, a bidirectional as-
sociation between depression and obesity was observed, 
that is, obese people had a 55% increased risk of devel-
oping depression over time, while depressed people had 
a 58% higher risk of becoming obese. The association be-
tween depression and obesity was stronger than the asso-
ciation between depression and overweight, which reflects 
a dose-response gradient15.
Studies refer to a higher prevalence of drug use for 
weight loss among women10,12. Regarding race/color, a 
study published by Cawley and Rizzo1 showed that there 
are discrepant dierences related to the use of appetite 
suppressant drugs among race/color, gender, and indi-
viduals with health insurance. The authors found that 
African-American individuals are considerably less prone 
to use appetite suppressant drugs, which arouses concern 
because obesity rates are higher among this group of peo-
ple. In Brazil, the prevalence of overweight and obesity was 
higher among black women16, which can be related to the 
di culty this population has to access dierent treatment 
modalities, including appetite suppressant drugs. In our 
study, a group of individuals of all ages in FEM and RAC 
variables may be an explanation for obtaining a signal that 
is not coherent with the denition of the study hypoth-
eses which deserves further research including individuals 
aged  18 years in the econometric model. 
Regarding the REN variable, the coe cient signal was 
also not coherent with the study hypothesis. A possible ex-
planation is that this portion of the Brazilian population 
has more advantaged economic conditions which allow 
them to have access to other obesity treatment modali-
ties, such as bariatric surgery and a diet supervised by a 
skilled professional. In Brazil, the Household Budget Sur-
vey (HBS) performed in 2002-2003 evidenced a direct as-
sociation between obesity and family income for men, and 
among the women of the highest income group the obesity 
prevalence was lower17. Might these ndings indicate that 
lower income women have searched for several obesity 
treatment modalities, such as the use of appetite suppres-
sant drugs? A population-based study performed in Pelo-
tas (Brazil) shows that more than 1% of the population 
has used some amphetamine derivative over the past two 
weeks, and the use of such drugs as appetite suppressants 
was higher among women in high education and income 
groups18. As to the colinearity among the ESC and REN 
variables, the literature evidences that income increase is 
strongly related to the number of years that individuals 
have studied19,20. 
The angular coe cient of IDA and TCP variables, al-
though estimated with a correct signal, that is, they ful-
lled what was proclaimed by the study hypothesis, in our 
econometric model, do not influence the use of appetite 
suppressant drugs in the UF. Data published by the Min-
istry of Health indicate that for both genders overweight 
frequency, as well as the number of obese people, tends to 
grow with age6.
In Brazil, the use of amphetamine derivatives (amphe-
pramone, fenproporex and mazindol) has fallen from over 
6.97 the dened daily dose (DDD)/thousand inhabitants/
day in 1993-1995 to 2.27 DDD/thousand inhabitants/day 
between 1997 and 1999. However, after this period, the use 
has reached the amount of 9.1 DDD/thousand inhabit-
ants/day in the biennial 2002-200421. A retrospective study 
performed in the city of Belo Horizonte, in Minas Gerais, 
showed an estimated use of 19.75 DDD/thousand inhabit-
ants/day in 2003. Another study also conducted in Belo 
Horizonte, in 2002, found an amphetamine derivatives use 
of 15 and 18 DDD/thousand inhabitants/day, in the rst 
and second semesters, respectively10. In subsequent years, 
Brazil became known as the world champion in the use 
of slimming drugs21. However, data published by Anvisa 
revealed a signicant reduction in the use of appetite sup-
pressant drugs by the Brazilian population in 2009. The 
DDD/thousand inhabitants/day for amphepramone, fen-
proporex, and mazindol was 0.61, 0.62, and 0.035, respec-
tively. The use of sibutramine was 2.78 DDD/thousand 
inhabitants/day22.
For Carneiro, Guerra Júnior, and Acúrcio10, the gold 
standard of weight-loss formulas is formed by an anorexi-
genic, an anxiolytic and a laxative. In our study, the coef-
cient of the chlordiazepoxide drug use variable presented 
a signal that is contrary to the study hypothesis, but it is 
not statistically signicant. Obesity in women is associated 
with the use of anxiolytics, antidepressives, sleep distur-
bances, and low level of life satisfaction23. 
We believe that an analysis of data in a municipal ag-
gregation level may establish new variables that are sta-
tistically signicant and coherent in terms of logical sig-
nal, as indicated by evidences available in the literature, 
as well as the inclusion of other variables, such as obese 
population and people who are overweight associated with 
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comorbidities (e.g., psychiatric problems)15,23. Such vari-
ables would be important in the econometric model to an-
swer the following question: Is the process of prescription-
indication of appetite suppressant drugs in the country a 
rational one?
An important point for pharmacoeconometrics studies 
is the precision of data to be inserted in the model aiming 
at an adequate statistical inference.  In our study, the sales 
data of the appetite suppressant drugs were used as a proxy 
for these drugs consumption in the country. The SNGPC 
keeps accounts of the use of drugs sold in private phar-
macies/drugstores, while some chains of these establish-
ments, by a court order, do not send  the balance of buying 
and selling to the system. Two other important points that 
interfere with the estimate of the use of the studied drugs 
are: 1) operational problems at SNGPC  may have along 
the year  prevented the receipt of XML les containing the 
balances of buying and selling of drugs; 2) as these prod-
ucts many times are the object of interest for illicit sales, 
some physical units used by part of the populations may 
not have been captured by SNGPC.
The empirical evidences arising from this study may 
contribute to improve regulatory actions, sanitary surveil-
lance, and ethical conduct, reviewing and amplifying the 
discussion of the concomitant use of these products with 
fluoxetine, which is prohibited by a resolution issued by 
the Federal Council of Medicine24, besides being prohib-
ited by a norm published by Anvisa25. 
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